Cargando…
Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients
Background: Psoriasis is a common immune-mediated skin disease that involves T-cell-mediated immunity. Invariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation that share properties and express surface markers of both NK cells and T cells. Previous reports indicate that iNKT cel...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850372/ https://www.ncbi.nlm.nih.gov/pubmed/35186952 http://dx.doi.org/10.3389/fcell.2021.799560 |
_version_ | 1784652583211630592 |
---|---|
author | Hu, Yifan Chen, Youdong Chen, Zeyu Zhang, Xilin Guo, ChunYuan Yu, ZengYang Xu, Peng Sun, Lei Zhou, Xue Gong, Yu Yu, Qian Shi, Yuling |
author_facet | Hu, Yifan Chen, Youdong Chen, Zeyu Zhang, Xilin Guo, ChunYuan Yu, ZengYang Xu, Peng Sun, Lei Zhou, Xue Gong, Yu Yu, Qian Shi, Yuling |
author_sort | Hu, Yifan |
collection | PubMed |
description | Background: Psoriasis is a common immune-mediated skin disease that involves T-cell-mediated immunity. Invariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation that share properties and express surface markers of both NK cells and T cells. Previous reports indicate that iNKT cells regulate the development of various inflammatory diseases. IL-17 is a key cytokine in the pathogenesis of psoriasis and a key therapeutic target. Secukinumab is a fully human IgG1κ antibody that targets IL-17A, thereby antagonizing the biological effects of IL-17. Objective: To explore the expression of iNKT cells in psoriasis patients and the effect of secukinumab on them. Methods: We examined the frequencies of iNKT cells, Tregs, naïve and memory CD4(+)and CD8(+)T cells in the PBMCs as well as their cytokine production in a cohort of 40 patients with moderate-to-severe plaque psoriasis and 40 gender- and age-matched healthy controls. We further collected peripheral blood of another 15 moderate-to-severe plaque psoriasis patients who were treated with secukinumab and evaluated the proportion of iNKT cells in the PBMCs at baseline and week 12. Results: The frequencies of conventional CD4(+) T cells, CD8(+) T cells, and Tregs in the PBMCs were comparable between psoriasis patients and healthy controls, but the frequencies of Th17 cells, Tc1 cells and Tc17 cells were increased in psoriasis patients. The frequency of peripheral iNKT cells and CD69(+) iNKT cells was significantly decreased in psoriasis patients. Both iNKT2 cells and iNKT17 cells were increased in psoriasis patients, but the ratio of iNKT2 cells vs iNKT17 cells was significantly reduced in psoriasis patients. After receiving secukinumab, the proportion of iNKT cells in the PBMCs of patients was increased, while the proportion of iNKT17 cells was decreased. Conclusion: Dysregulated iNKT cells may be involved in the pathogenesis of psoriasis and secukinumab may play a regulatory role on iNKT cells. |
format | Online Article Text |
id | pubmed-8850372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88503722022-02-18 Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients Hu, Yifan Chen, Youdong Chen, Zeyu Zhang, Xilin Guo, ChunYuan Yu, ZengYang Xu, Peng Sun, Lei Zhou, Xue Gong, Yu Yu, Qian Shi, Yuling Front Cell Dev Biol Cell and Developmental Biology Background: Psoriasis is a common immune-mediated skin disease that involves T-cell-mediated immunity. Invariant natural killer T (iNKT) cells are a unique lymphocyte subpopulation that share properties and express surface markers of both NK cells and T cells. Previous reports indicate that iNKT cells regulate the development of various inflammatory diseases. IL-17 is a key cytokine in the pathogenesis of psoriasis and a key therapeutic target. Secukinumab is a fully human IgG1κ antibody that targets IL-17A, thereby antagonizing the biological effects of IL-17. Objective: To explore the expression of iNKT cells in psoriasis patients and the effect of secukinumab on them. Methods: We examined the frequencies of iNKT cells, Tregs, naïve and memory CD4(+)and CD8(+)T cells in the PBMCs as well as their cytokine production in a cohort of 40 patients with moderate-to-severe plaque psoriasis and 40 gender- and age-matched healthy controls. We further collected peripheral blood of another 15 moderate-to-severe plaque psoriasis patients who were treated with secukinumab and evaluated the proportion of iNKT cells in the PBMCs at baseline and week 12. Results: The frequencies of conventional CD4(+) T cells, CD8(+) T cells, and Tregs in the PBMCs were comparable between psoriasis patients and healthy controls, but the frequencies of Th17 cells, Tc1 cells and Tc17 cells were increased in psoriasis patients. The frequency of peripheral iNKT cells and CD69(+) iNKT cells was significantly decreased in psoriasis patients. Both iNKT2 cells and iNKT17 cells were increased in psoriasis patients, but the ratio of iNKT2 cells vs iNKT17 cells was significantly reduced in psoriasis patients. After receiving secukinumab, the proportion of iNKT cells in the PBMCs of patients was increased, while the proportion of iNKT17 cells was decreased. Conclusion: Dysregulated iNKT cells may be involved in the pathogenesis of psoriasis and secukinumab may play a regulatory role on iNKT cells. Frontiers Media S.A. 2022-02-03 /pmc/articles/PMC8850372/ /pubmed/35186952 http://dx.doi.org/10.3389/fcell.2021.799560 Text en Copyright © 2022 Hu, Chen, Chen, Zhang, Guo, Yu, Xu, Sun, Zhou, Gong, Yu and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Hu, Yifan Chen, Youdong Chen, Zeyu Zhang, Xilin Guo, ChunYuan Yu, ZengYang Xu, Peng Sun, Lei Zhou, Xue Gong, Yu Yu, Qian Shi, Yuling Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients |
title | Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients |
title_full | Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients |
title_fullStr | Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients |
title_full_unstemmed | Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients |
title_short | Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients |
title_sort | dysregulated peripheral invariant natural killer t cells in plaque psoriasis patients |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850372/ https://www.ncbi.nlm.nih.gov/pubmed/35186952 http://dx.doi.org/10.3389/fcell.2021.799560 |
work_keys_str_mv | AT huyifan dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT chenyoudong dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT chenzeyu dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT zhangxilin dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT guochunyuan dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT yuzengyang dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT xupeng dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT sunlei dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT zhouxue dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT gongyu dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT yuqian dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients AT shiyuling dysregulatedperipheralinvariantnaturalkillertcellsinplaquepsoriasispatients |